Nuwellis (NUWE) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $2.4 million, down 2% year-over-year but up 8% sequentially, mainly due to lower consumables and US console sales, partially offset by a one-time increase in SeaStar Medical Quelimmune sales.

• Gross margin improved to 70% from 57.3% in Q3 2023, attributed to higher manufacturing volumes, consumables, and lower overhead.

• Net income was $2.4 million, or $1.74 per share, versus a net loss of $3.4 million, or $63.27 per share, in Q3 2023, mainly due to a $3.9 million warrant liability revaluation benefit.

• The company implemented cost reduction measures, including workforce and salary cuts, reducing cash burn by 40%.

• Recent capital raises and warrant exercises provided short-term liquidity, but ongoing operating losses and negative cash flows persist.

Financial highlights

• SG&A expenses fell 21% to $2.7 million, and R&D expenses dropped to $486,000 from $1.1 million year-over-year.

• Total operating expenses decreased 30% to $3.2 million, driven by efficiency initiatives.

• Operating loss improved to $1.5 million from $3.2 million in Q3 2023.

• Cash and cash equivalents were $1.9 million as of September 30, 2024, with no debt and shareholder equity of $3.2 million.

• Net cash used in operations for the nine months ended September 30, 2024, was $8.1 million, improved from $15.2 million in the prior year.

Outlook and guidance

• CMS reimbursement for Aquadex facility fee will increase 297% to $1,639 per day effective January 1, 2025, expanding the outpatient market opportunity.

• Management anticipates accelerated top-line growth in 2025 and positive impact from new clinical results and reimbursement changes.

• Existing capital resources are expected to support operations through May 31, 2025; additional capital raises may be required.

• No immediate need to expand field personnel; may add reimbursement expertise at headquarters.